Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMS | P04818 | 10/20 | 0.63 |
| ▸ | FOLR1 | P15328 | 5/20 | 0.63 |
| ▸ | SLC19A1 | P41440 | 5/20 | 0.63 |
| ▸ | SLC46A1 | Q96NT5 | 5/20 | 0.63 |
| ▸ | DHFR | P00374 | 4/20 | 0.63 |
| ▸ | GART | P22102 | 3/20 | 0.63 |
| ▸ | FOLR2 | P14207 | 1/20 | 0.63 |
| ▸ | ATIC | P31939 | 1/20 | 0.63 |
| ▸ | SHMT1 | P34896 | 1/20 | 0.63 |
| ▸ | FRK | P42685 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1302244 | 1.00 | TYMS (0.63) | TYMSFOLR1SLC19A1SLC46A1DHFR | |
| SCHEMBL2607964 | 0.91 | GART (0.77) | TYMSFOLR1SLC19A1SLC46A1DHFR | |
| SCHEMBL1302278 | 0.89 | TYMS (0.79) | TYMSFOLR1SLC19A1SLC46A1DHFR | |
| SCHEMBL1302274 | 0.89 | TYMS (0.79) | TYMSFOLR1SLC19A1SLC46A1DHFR | |
| SCHEMBL12107866 | 0.88 | TYMS (0.46) | TYMSFOLR1SLC19A1SLC46A1DHFR | |
| SCHEMBL16328813 | 0.88 | TYMS (0.46) | TYMSFOLR1SLC19A1SLC46A1DHFR | |
| SCHEMBL2610601 | 0.85 | TYMS (0.61) | TYMSFOLR1SLC19A1SLC46A1DHFR | |
| SCHEMBL12314803 | 0.85 | TYMS (0.60) | TYMSFOLR1SLC19A1SLC46A1DHFR | |
| SCHEMBL20207399 | 0.83 | TYMS (0.59) | TYMSFOLR1SLC19A1SLC46A1DHFR | |
| SCHEMBL20207405 | 0.83 | TYMS (0.59) | TYMSFOLR1SLC19A1SLC46A1DHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2323695-B1 | COMPLEXES OF SMALL-INTERFERING NUCLEIC ACIDS | NEKTAR THERAPEUTICS (US) | 2018-12-05 | — | — | EP | disclosed |
| EP-2326351-B1 | CONJUGATES OF SMALL-INTERFERING NUCLEIC ACIDS | NEKTAR THERAPEUTICS (US) | 2017-12-27 | — | — | EP | disclosed |
| US-9433684-B2 | Conjugates of small-interfering nucleic acids | NEKTAR THERAPEUTICS (US) | 2016-09-06 | — | — | US | disclosed |
| US-9089610-B2 | Complexes of small-interfering nucleic acids | NEKTAR THERAPEUTICS (US) | 2015-07-28 | — | — | US | disclosed |
| US-20120100096-A1 | CONJUGATES PF SMALL-INTERFERING NUCLEIC ACIDS | NEKTAR THERAPEUTICS (US) | 2012-04-26 | — | — | US | disclosed |
| US-20110269713-A1 | BRYOSTATIN ANALOGUES AND METHODS OF MAKING AND USING THEREOF | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110213013-A1 | Complexes of Small-Interfering Nucleic Acids | NEKTAR THERAPEUTICS (US) | 2011-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269713-A1 | BRYOSTATIN ANALOGUES AND METHODS OF MAKING AND USING THEREOF | PRKAR2B, PRKAR2A, PRKCH | TYMS 1710/4885FOLR1 2005/4885SLC19A1 4362/4885 |
| US-20120100096-A1 | CONJUGATES PF SMALL-INTERFERING NUCLEIC ACIDS | SLC19A1, FOLR1, SLC46A1 | TYMS 1066/4885FOLR1 2/4885SLC19A1 1/4885 |
| US-20110213013-A1 | Complexes of Small-Interfering Nucleic Acids | SNRPA, NSUN2, SNRPE | TYMS 1796/4885FOLR1 822/4885SLC19A1 458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.